Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair

The median survival for patients with locally advanced pancreatic cancer treated with gemcitabine and radiation is approximately one year. To develop improved treatment, we have combined a Chk1/2 targeted agent, AZD7762, currently in Phase I clinical trials, with gemcitabine and ionizing radiation i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Morgan, Meredith A., Parsels, Leslie A., Zha, Lili, Parsels, Joshua D., Davis, Mary A., Hassan, Maria C., Arumugarajah, Sankari, Hylander-Gans, Linda, Morosini, Deborah, Simeone, Diane M., Canman, Christine E., Normolle, Daniel P., Zabludoff, Sonya D., Maybaum, Jonathan, Lawrence, Theodore S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2889008/
https://ncbi.nlm.nih.gov/pubmed/20501833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-3573
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi